Briacell Therapeutics Ownership
| BCTX Stock | USD 0.66 0.44 40.00% |
Shares in Circulation | First Issued 2006-09-30 | Previous Quarter 16 M | Current Value 16.5 M | Avarage Shares Outstanding 3.1 M | Quarterly Volatility 6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Briacell |
Briacell Stock Ownership Analysis
About 20.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.29. Briacell Therapeutics last dividend was issued on the 2nd of January 2020. The entity had 1:300 split on the 2nd of January 2020. BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada. BriaCell Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. For more info on Briacell Therapeutics Corp please contact William MD at 604-921-1810 or go to https://briacell.com.Besides selling stocks to institutional investors, Briacell Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Briacell Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Briacell Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Briacell Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 20.0% of Briacell Therapeutics Corp are currently held by insiders. Unlike Briacell Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Briacell Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Briacell Therapeutics' insider trades
Briacell Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Briacell Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Briacell Therapeutics Corp backward and forwards among themselves. Briacell Therapeutics' institutional investor refers to the entity that pools money to purchase Briacell Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Concord Wealth Partners | 2024-09-30 | 14.1 K | Susquehanna International Group, Llp | 2024-09-30 | 13.9 K | Royal Bank Of Canada | 2024-09-30 | 3.8 K | Td Waterhouse Canada Inc | 2024-09-30 | 2.9 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.7 K | Advisor Group Holdings, Inc. | 2024-09-30 | 1000 | Hhm Wealth Advisors, Llc | 2024-09-30 | 1000 | Ubs Group Ag | 2024-09-30 | 794 | Simplex Trading, Llc | 2024-09-30 | 323 | Vontobel Holding Ltd. | 2024-09-30 | 80 K | Hrt Financial Llc | 2024-09-30 | 74.3 K |
Briacell Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Briacell Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Briacell Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Briacell Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Embro-pantalony Vaughn C. over a month ago Disposition of 50000 shares by Embro-pantalony Vaughn C. of Briacell Therapeutics at 8.47 subject to Rule 16b-3 | ||
Williams Williams V. over three months ago Disposition of 27272 shares by Williams Williams V. of Briacell Therapeutics at 5.31 subject to Rule 16b-3 | ||
Lustig Marc over six months ago Acquisition by Lustig Marc of 902935 shares of Briacell Therapeutics at 2.11 subject to Rule 16b-3 | ||
Williams Williams V. over six months ago Disposition of 22300 shares by Williams Williams V. of Briacell Therapeutics at 8.47 subject to Rule 16b-3 | ||
Williams William V over six months ago Purchase by Williams William V of 2530 shares of Briacell Therapeutics | ||
Williams William V over a year ago Briacell Therapeutics exotic insider transaction detected |
Briacell Therapeutics Outstanding Bonds
Briacell Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Briacell Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Briacell bonds can be classified according to their maturity, which is the date when Briacell Therapeutics Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Briacell Stock Analysis
When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.